A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 May 2015
At a glance
- Drugs Neratinib (Primary) ; Vinorelbine
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Puma Biotechnology
- 14 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
- 17 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 30 Jan 2013 Planned end date changed from 1 Apr 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.